Genentech Licenses SanegeneBio RNAi Program in Deal Worth Up to $1.7 Billion

Overview

• The agreement grants Genentech exclusive global rights to an undisclosed RNAi program with $200 million upfront, up to $1.5 billion in milestones, and tiered royalties.
• SanegeneBio will run early development, while Genentech will lead all subsequent clinical development and worldwide commercialization.
• The collaboration leverages SanegeneBio’s RNAi platform featuring new chemistries and tissue-selective delivery technologies for siRNA medicines across multiple disease areas.
• SanegeneBio’s pipeline has advanced into the clinic, including recent first dosing of obesity candidate SGB-7342 in China and positive Phase I signals for C3-targeting SGB-9768 and AGT-targeting SGB-3908.
• The deal follows SanegeneBio’s growth moves, including a Series B raise of more than $110 million and a 2025 research and licensing partnership with Eli Lilly for metabolic diseases.